CompletedPhase 4

Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest

France2,416 participantsStarted 2004-05-02

Plain-language summary

Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests. The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine. The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients. The primary endpoint is the survival rate at hospital admission. The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.

Who can participate

Age range

18 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Out-of-hospital medical cardiac arrest in adult patients. Exclusion Criteria: * Traumatic cardiac arrest * Pregnancy * Patients younger than 18 years old or older than 85 years old

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial compared vasopressin plus epinephrine against epinephrine alone during cardiac arrest — since it's already completed, can you tell me what the results showed and whether they changed the way you approach resuscitation today?
2The trial only measured survival up to hospital admission as its main goal — do you know if there's any follow-up data on whether patients who survived to admission also made it to discharge or had good long-term outcomes?
3Since this was a Phase 4 trial, meaning both drugs were already approved when it ran, does that mean the safety profile of combining vasopressin and epinephrine is considered well understood, and is that combination something used in current resuscitation guidelines?
4Given that this study is completed, is the vasopressin-plus-epinephrine approach still being used in practice, or did the results lead doctors back to epinephrine alone as the standard of care?
5If I or a family member were ever in cardiac arrest, how would knowing about this trial's findings affect the treatment decisions your team would make in the emergency setting?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Survival at hospital admission

Trial details

NCT IDNCT00127907

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-10-01

View on ClinicalTrials.gov More Cardiac Arrest trials